Urinary Metabolite Testing for Certain Wastewater Treatment Facilities
Impact
Once enacted, the bill will require testing to occur quarterly, with samples collected from various municipal and regional wastewater treatment facilities, particularly those near larger populations. The integration of this testing into state practices is anticipated to enhance monitoring efforts and improve transparency in reporting results to the public. This could potentially lead to more stringent regulations regarding wastewater management in South Carolina, holding facilities accountable for contaminants found in processed water.
Summary
House Bill H4655 proposes amendments to the South Carolina Code of Laws, specifically by adding Article 25 to Chapter 55, Title 44. This legislation mandates the Department of Environmental Services to conduct regular testing for specific urinary metabolites at designated wastewater treatment facilities. The primary focus of the bill is to ensure that wastewater management practices are scrutinized for the presence of hazardous chemicals that could pose risks to public health and the environment.
Contention
The bill’s implications extend to environmental regulations and public health policies in the state. Proponents emphasize the need for improved oversight in environmental safeguards, particularly concerning substances known to disrupt endocrine functions and other health effects linked to urban wastewater. There may be contention surrounding funding the required testing, the selection of facilities for sampling, and how results will influence future regulatory changes. Critics may argue about the potential challenges or expenses that could arise for small municipalities while ensuring compliance with the new law.
Children: child abuse or child neglect; mandatory reporting of certain events at birth of a child; modify. Amends sec. 3a of 1975 PA 238 (MCL 722.623a).
Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of diagnosing and treating infertility, for women between the ages of 25 and 42 years including preimplantation genetic diagnosis (PGD) in conjunction with IVF.